Imaging how head and neck cancer responds to treatment
Part of Cancer clinical trials.
This trial tests a new imaging technique that uses a radioactive tracer to see how your cancer cells respond to DNA damage from treatment. The goal is to help doctors personalize your chemoradiation therapy by seeing if the treatment is working early on.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older (if your cancer is HPV-negative) or 40 or older (if your cancer is HPV-positive) and have a history of heavy smoking.
- Your treatment plan will include chemotherapy (with a platinum drug) and radiation therapy.
- You need to have a recent tumor sample (biopsy) from the last 8 weeks that can be tested for a specific protein.
- You must have a tumor that is at least 10 millimeters in size.
- You should be in relatively good health (able to care for yourself) and not have taken certain cancer drugs in the last month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental PET scan that may help doctors see how well standard radiation and chemotherapy are working for advanced head and neck cancer. It aims to improve treatment planning by tracking a specific molecule in the body.
This study tests a special PET/CT scan that may help doctors see the cancer more clearly in people with head and neck cancer, either at diagnosis or if it comes back.
This trial tests a new type of PET scan that uses a special tracer (68Ga-FAPI-46) to see if it can better show the extent of head and neck cancers before surgery. It may help doctors plan your treatment more accurately.
This early-phase study tests whether adding a medicine called a PARP inhibitor to peptide receptor radionuclide therapy (PRRT) can better control advanced or metastatic neuroendocrine tumors (NET). It may help by targeting tumor DNA repair while PRRT delivers targeted radiation.
This trial is testing whether a newer type of PET/CT scan (F-18 NaF) can better detect blood vessel problems caused by radiation therapy than the standard scan (F-18 FDG) in people with head and neck cancer. If successful, it could lead to better ways to prevent and manage these complications.
This trial uses a special PET scan and a blood test to see if a PARP inhibitor (a type of targeted therapy) will work for metastatic prostate cancer. It aims to predict treatment response early so you can get the best care.
Hear when a new Head and Neck Squamous Cell Carcinoma (HNSCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.